FindTrial
Sign In

URINE BIOMARKER SCREENING FOR PROSTATE CANCER

Establishment and Validation of Urine Biomarkers before Prostate Biopsy: A Sequential-Enrollment, Blinded Study

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2021/09/036323
Enrollment
30
Registered
2021-09-07
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: N429- Disorder of prostate, unspecified

Interventions

Intervention1: NIL: NIl

Sponsors

Medicametrix
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Cohort randomized prospective study, signed informed consent, Male between age 45 AND 85 suspected case of prostate cancer (PCa) before biospy, Total PSA & Free PSA, 4K Score/PHI, Prostate volume, Testoterone, Routine urine analysis, Biochemical test,transrectal ultrasound (TRUS)-guided biopsies or DRE, MR Scan,microscopic anatomy, Gleason Score and estimates the overall â??Cancer Aggressivenessâ?? Score Sandwich Elisa.

Exclusion criteria

Exclusion criteria: Patients come for second and third opinions, Unable to perform a Rectal Examination or any reason, Certain Lower Urinary Tract Congenital Abnormalities inability to understand or give informed consent, Patients with history of HIV, HBV, TB.

Design outcomes

Secondary

MeasureTime frame
Validation of selected urinary biomarkers for pilot studyTimepoint: One Year—

Primary

MeasureTime frame
Identify whether selected panels of urinary biomarkers before prostate biopsy that will provide promising novel tool to guide clinical decision making for prostate cancer (PCa) treatment and management.Timepoint: One Year—

Countries

India

Contacts

Public ContactDrMahesh Desai

Muljibhai Patel Urological Hospital

mrdesai@mpuh.org

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026